You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 28, 2026

Claims for Patent: 12,503,469

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,503,469

Title:	Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate
Abstract:	This present invention relates to forms of methyl {4.6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3.4-b]pyridino-3-yl]pyrimidino-5-yl}methylcarbamate comprising its Modification I, Modification II, mono-DMSO solvate, sesqui-DMSO solvate and ¼-ethyl acetated solvate.
Inventor(s):	Birgit Keil, Franz-Josef Mais, Winfried Joentgen, Alfons Grunenberg
Assignee:	Bayer Intellectual Property GmbH , Adverio Pharma GmbH
Application Number:	US17/526,129
Patent Claims:	1. A pharmaceutical composition comprising a compound of the formula (I) and a pharmaceutically acceptable carrier, in which 100 percent by weight relative to the total weight of all forms of the compound of formula (I) in the composition is in crystalline form of Modification (I), wherein the compound of the formula (I) is characterized by an X-Ray powder diffractogram comprising peak maxima of the 2 Theta angle of 6.7, 9.1 and 17.8. 2. A method for the treatment of pulmonary arterial hypertension comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 1 to a patient in need thereof. 3. A method for the treatment of pulmonary hypertension associated with thromboembolism (CTEPH) comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 1 to a patient in need thereof. 4. A method for the treatment of pulmonary arterial hypertension comprising administering a composition comprising a therapeutically effective amount of a compound of the formula (I) and a pharmaceutically acceptable carrier, in which more than 90 percent by weight relative to the total weight of all forms of the compound of formula (I) in the composition is in the crystalline form of Modification I, to a patient in need thereof, wherein the compound of the formula (I) has an X-Ray powder diffractogram comprising peak maxima of the 2 Theta angle of 6.7, 9.1 and 17.8. 5. A method for the treatment of pulmonary hypertension associated with thromboembolism (CTEPH) comprising administering a composition comprising a therapeutically effective amount of a compound of the formula (I) and a pharmaceutically acceptable carrier, in which more than 90 percent by weight relative to the total weight of all forms of the compound of formula (I) in the composition is in the crystalline form of Modification I, to a patient in need thereof, wherein the compound of the formula (I) has an X-Ray powder diffractogram comprising peak maxima of the 2 Theta angle of 6.7, 9.1 and 17.8.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.